Genscript Biotech (HK:1548) has released an update.
Genscript Biotech Corporation announced the unaudited financial results for the third quarter of 2024 for its associate, Legend Biotech Corporation, which holds a 47.56% stake in the company. Legend Biotech, listed on the Nasdaq Global Selected Market, has filed its results with the SEC, highlighting important business developments. Investors are advised to consider potential risks when dealing with Genscript’s securities.
For further insights into HK:1548 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- M&A News: Paramount’s (NASDAQ:PARA) Merger with Skydance May Get Delayed
- Ford (NYSE:F) Cuts Hours At German EV Plant
- Did Intel (NASDAQ:INTC) Win the “Server Recession?”
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
